Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients

Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).The primary endpoint in the CORAL trial was achieved, demonstrating statistically significant reductions in 24-hour cough frequency across all dose groups at week six.Also Read: Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock JumpsThe 108 mg BID, 54 mg BID and 27 mg BID dose gr ...